SENTI-202 CAR NK Cell Therapy Achieves Complete Remission in Four R/R AML Patients in Phase 1 Trial

A phase 1 clinical trial evaluating a novel cancer therapy showed promising results in patients with relapsed or refractory acute myeloid leukemia (AML). Specifically, the interim results of the SENTI-202-101 trial indicate that four patients with R/R AML achieved complete remission after receiving SENTI-202. SENTI-202 is a logic-gated, off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy. The ongoing SENTI-202-101 trial is designed to assess the safety and efficacy of SENTI-202 in individuals with AML that has either returned after treatment (relapsed) or has not responded to previous treatments (refractory). The therapy uses CAR NK cells, which are engineered immune cells designed to target and destroy cancer cells. The “logic-gated” aspect of the therapy implies that the CAR NK cells are designed with specific controls to enhance their precision and minimize potential side effects. The “off-the-shelf” designation means the therapy is readily available for use, rather than being manufactured on a patient-by-patient basis.

Newsflash | Powered by GeneOnline AI
Date: April 27, 2025

Related posts:

Pharmacists Highlight Molecular Structure’s Impact on HER2-Targeted Drug Efficacy in Breast Cancer Treatment. Healthcare Providers Face Obstacles in Preventing CDS Bias Due to Lack of Regulatory Guidance Active Recall Boosts Retention by 20%, Study Finds HHS Review Recommends Behavioral Therapy First for Gender Dysphoric Youth, Cites Cautious Approach to Medical Interventions

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後